Cardiff Oncology Q3 2023 Earnings Preview
CRDF Stock | USD 2.61 0.07 2.76% |
Roughly 68% of Cardiff Oncology's investor base is looking to short. The analysis of the overall investor sentiment regarding Cardiff Oncology suggests that many traders are alarmed. The current market sentiment, together with Cardiff Oncology's historical and current headlines, can help investors time the market. In addition, many technical investors use Cardiff Oncology stock news signals to limit their universe of possible portfolio assets.
Cardiff |
Cardiff Oncology is set to release its Q3 earnings results, with a consensus EPS estimate of -0.28 and a revenue estimate of 0.04M, showing a decline in...
Read at seekingalpha.com
Cardiff Oncology Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Cardiff Oncology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Cardiff Oncology Fundamental Analysis
We analyze Cardiff Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cardiff Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cardiff Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
Cardiff Oncology is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Cardiff Oncology Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cardiff Oncology stock to make a market-neutral strategy. Peer analysis of Cardiff Oncology could also be used in its relative valuation, which is a method of valuing Cardiff Oncology by comparing valuation metrics with similar companies.
Peers
Cardiff Oncology Related Equities
CUE | Cue Biopharma | 11.93 | ||||
LYRA | Lyra Therapeutics | 10.53 | ||||
RVPH | Reviva Pharmaceuticals | 8.77 | ||||
NLSP | NLS Pharmaceutics | 3.36 | ||||
LTRN | Lantern Pharma | 3.22 | ||||
RNAZ | Transcode Therapeutics | 2.94 | ||||
CGEM | Cullinan Oncology | 2.75 | ||||
PDSB | PDS Biotechnology | 1.86 | ||||
KOD | Kodiak Sciences | 1.83 | ||||
BOLT | Bolt Biotherapeutics | 1.59 | ||||
AUTL | Autolus Therapeutics | 1.53 | ||||
DAWN | Day One | 1.53 | ||||
MREO | Mereo BioPharma | 1.40 | ||||
CGTX | Cognition Therapeutics | 2.44 | ||||
INAB | In8bio | 3.23 | ||||
SLS | Sellas Life | 3.42 | ||||
RVPHW | Reviva Pharmaceuticals | 4.35 |
Complementary Tools for Cardiff Stock analysis
When running Cardiff Oncology's price analysis, check to measure Cardiff Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cardiff Oncology is operating at the current time. Most of Cardiff Oncology's value examination focuses on studying past and present price action to predict the probability of Cardiff Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cardiff Oncology's price. Additionally, you may evaluate how the addition of Cardiff Oncology to your portfolios can decrease your overall portfolio volatility.
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |